carmot glp-1 Roche's GLP1/GIP drug sees 22.5% weight loss, readies ph. 3 push Current Perspectives on GLP-1 Agonists

Phase 2 Clinical Trial# The Phase 2 trial enrolled 469 adults with obesity or overweight and evaluated three subcutaneous dose levels of CT-388 versus placebo over 48 weeks

You receive help through counseling, therapy, and educational sessions while still living at home

This matters because injections are a barrier for some patients

Roos, S

Patients should be empowered as active participants in treatment decisions, with ongoing dialogue about benefits, risks, and treatment goals tailored to their individual circumstances

It aims to provide a more comprehensive safety profile using real-world data for clinicians and regulators